Search hospitals > Delaware > Newark
Medical Oncology Hematology Consultants PA
Claim this profileNewark, Delaware 19713
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Tumors
250 reported clinical trials
3 medical researchers
Summary
Medical Oncology Hematology Consultants PA is a medical facility located in Newark, Delaware. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Tumors and other specialties. Medical Oncology Hematology Consultants PA is involved with conducting 250 clinical trials across 379 conditions. There are 3 research doctors associated with this hospital, such as Gregory A. Masters, Jamal Misleh, MD, and Mark E. Borowsky.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Gregory A. MastersHelen F Graham Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
121 reported clinical trials
200 drugs studied
Jamal Misleh, MDMedical Oncology Hematology Consultants, PA1 year of reported clinical research
Expert in Breast Cancer
Studies Cancer
26 reported clinical trials
46 drugs studied
Mark E. BorowskyJersey Shore Medical Center12 years of reported clinical research
Studies Serous Cystadenocarcinoma
Studies Adenocarcinoma
3 reported clinical trials
11 drugs studied
Clinical Trials running at Medical Oncology Hematology Consultants PA
Breast Cancer
Lung Cancer
Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Colorectal Cancer
Squamous Cell Carcinoma
Tumors
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Medical Oncology Hematology Consultants PA?
Medical Oncology Hematology Consultants PA is a medical facility located in Newark, Delaware. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Tumors and other specialties. Medical Oncology Hematology Consultants PA is involved with conducting 250 clinical trials across 379 conditions. There are 3 research doctors associated with this hospital, such as Gregory A. Masters, Jamal Misleh, MD, and Mark E. Borowsky.